Rallybio Quarterly Balance Sheet
NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Rallybio financial position
As of Sep 30, 2026, Rallybio reported total assets of $95.6 million, up 41.3% from a year earlier against total liabilities of $3.3 million. Shareholders' equity stood at $92.3 million, or 96.6% of assets. The company held $90.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 28.87, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Rallybio balance sheet (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 90.69M | 92.85M | 41.30M | 31.37M | 32.12M | 9.45M | 14.78M | 13.90M | 25.32M | 16.67M | 19.30M | 24.49M |
| Short-Term Investments | 0 | 0 | 5.50M | 23.36M | 27.20M | 36.30M | 39.72M | 51.61M | 49.82M | 71.94M | 74.87M | 85.44M |
| Total Current Assets | 94.77M | 97.25M | 53.49M | 61.25M | 66.63M | 50.27M | 57.38M | 67.84M | 78.23M | 91.44M | 98.55M | 114.79M |
| Property, Plant & Equipment | 0 | 0 | 20.00K | 23.00K | 26.00K | 61.00K | 87.00K | 115.00K | 145.00K | 177.00K | 211.00K | 246.00K |
| Total Assets | 95.58M | 98.06M | 54.47M | 62.26M | 67.66M | 51.00M | 57.98M | 68.11M | 79.01M | 92.43M | 99.36M | 115.62M |
| Accounts Payable | 7.00K | 833.00K | 940.00K | 126.00K | 269.00K | 119.00K | 400.00K | 278.00K | 583.00K | 1.22M | 470.00K | 976.00K |
| Total Current Liabilities | 3.28M | 3.57M | 4.14M | 4.22M | 4.52M | 5.04M | 3.91M | 6.24M | 8.19M | 12.16M | 10.09M | 9.26M |
| Total Liabilities | 3.28M | 3.57M | 4.20M | 4.30M | 4.63M | 5.04M | 3.91M | 6.45M | 8.19M | 12.41M | 10.20M | 9.44M |
| Shareholders' Equity | 92.30M | 94.50M | 50.28M | 57.96M | 63.03M | 45.96M | 54.07M | 61.65M | 70.82M | 80.02M | 89.16M | 106.18M |
| Retained Earnings | -269.34M | -266.61M | -310.28M | -302.00M | -296.15M | -312.16M | -302.46M | -293.02M | -281.98M | -270.51M | -254.27M | -235.25M |
| Net Cash (Debt) | 90.69M | 92.85M | 46.80M | 54.74M | 59.32M | 45.75M | 54.49M | 65.51M | 75.14M | 88.61M | 94.17M | 109.93M |
| Shares Outstanding | 5.33M | 5.31M | 5.29M | 5.28M | 41.94M | 41.71M | 41.61M | 5.19M | 41.49M | 41.49M | 37.81M | 37.83M |
This table shows 12 quarterly periods of Rallybio's balance sheet, from Q3 2026 back to Q4 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RLYB's reporting calendar. What is a balance sheet?